Bicycle Therapeutics financials
$3.65−1.62%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $629.0K | $887.0K | $48.0M | $11.7M | $2.9M | $10.0M | $3.7M | $2.7M | $9.4M | $19.5M | $5.3M | $5.4M |
| Gross profit | $629.0K | $887.0K | $48.0M | $11.7M | $2.9M | $10.0M | $3.7M | $2.7M | $9.4M | $19.5M | $5.3M | $5.4M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$54.6M | -$65.5M | -$24.7M | -$65.6M | -$86.6M | -$70.2M | -$67.7M | -$63.8M | -$46.6M | -$31.7M | -$54.2M | -$50.8M |
| Net income | -$50.3M | -$60.8M | -$20.2M | -$59.1M | -$79.0M | -$60.8M | -$51.9M | -$50.8M | -$39.8M | -$26.6M | -$49.1M | -$49.9M |
| Net margin | −8002.1% | −6857.4% | −42.0% | −503.7% | −2703.8% | −608.9% | −1398.4% | −1898.4% | −425.3% | −136.0% | −921.0% | −932.3% |
| Diluted EPS | $-0.72 | $-0.87 | $-0.29 | $-0.85 | $-1.14 | $-0.88 | $-0.75 | $-0.74 | $-0.77 | $-0.62 | $-1.15 | $-1.26 |
| EBITDA | -$53.5M | -$64.4M | -$23.4M | -$63.8M | -$84.9M | -$68.6M | -$66.0M | -$61.7M | -$45.0M | -$30.1M | -$52.6M | -$49.1M |
| Operating cash flow | -$49.6M | -$65.9M | -$19.3M | -$71.2M | -$72.8M | -$86.4M | -$9.4M | -$39.8M | -$44.6M | -$70.9M | -$47.3M | -$1.0M |
| Free cash flow | -$49.9M | -$66.6M | -$19.9M | -$71.8M | -$73.3M | -$87.0M | -$9.8M | -$40.3M | -$45.0M | -$70.9M | -$47.3M | -$1.5M |
| Diluted shares | 69.8M | 69.7M | 69.4M | 69.3M | 69.3M | 69.2M | 69.3M | 69.0M | 52.0M | 42.6M | 42.6M | 39.6M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $510.1M | $559.5M | $628.1M | $648.3M | $721.5M | $793.0M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $606.6M | $652.4M | $717.6M | $764.0M | $832.2M | $883.9M |
| Total liabilities | $96.3M | $98.1M | $107.6M | $145.5M | $163.3M | $143.6M |
| Shareholders' equity | $510.3M | $554.3M | $610.0M | $618.5M | $668.9M | $740.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology